SHBs Mitigates Sorafenib‐Induced Apoptosis in Hepatocellular Carcinoma via Activation of RAF1 / MEK / ERK Signaling Pathway
Cancer Science · 2025-09 · 116 (9) · 2471-2485
DOI: 10.1111/cas.70132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 28.06.2025. Verfasst von Shuxiang Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Gastrointestinal Cancer, (Fujian Medical University), Ministry of Education, Fuzhou, China. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Proto-Oncogene Proteins c-raf, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Joint Funds for the Innovation of Science and Technology in Fujian Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide, with a significant association to hepatitis B virus (HBV) infection, which has been shown to drive HCC progression. Sorafenib, a multi‐kinase inhibitor, is the first‐line treatment for advanced HCC. However, recent studies indicate that HBV infection may confer resistance to sorafenib treatment. The small hepatitis B surface antigen (SHBs), the most abundant HBV viral protein, has been implicated in HCC development, yet its role in sorafenib resistance is unclear. This study demonstrates that SHBs promotes sorafenib resistance in HCC cells and xenograft models by inhibiting apoptosis. Upon sorafenib treatment, SHBs expression was found to enhance the RAF1/MEK/ERK signaling pathway, as evidenced by increased phosphorylation of ERK and MEK. Inhibition of ERK activity with U0126 countered SHBs effects on sorafenib‐induced apoptosis, cleaved caspase‐3, and cellular proliferation. Mechanistically, SHBs binds to protein tyrosine phosphatase non‐receptor type 1 (PTPN1), enhancing its phosphorylation, which subsequently dephosphorylates the protein tyrosine phosphatase interacting protein 51 (PTPIP51). This dephosphorylation promotes RAF1 recruitment to the 14–3‐3β complex, leading to activation of the RAF1/MEK/ERK pathway. These findings suggest that SHBs prevents sorafenib‐induced apoptosis in HCC cells by binding to PTPN1 and stimulating the formation of the PTPIP51/14–3‐3β/RAF1 complex, thereby activating the RAF1/MEK/ERK signaling pathway. This mechanism provides insight into HBV‐induced sorafenib resistance in HCC, highlighting SHBs as a potential target for overcoming treatment resistance in HBV‐related HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Gastrointestinal Cancer, (Fujian Medical University), Ministry of Education, Fuzhou, China.
- Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China.
ORCID-Profile: Xu Lin
Förderung
- Joint Funds for the Innovation of Science and Technology in Fujian Province
- National Natural Science Foundation of China
Zitieren
APA
Wu, S., Hong, Y., Li, H., Lin, M., Lin, X., Lin, X., & Lin, X. (2025). SHBs Mitigates Sorafenib‐Induced Apoptosis in Hepatocellular Carcinoma via Activation of RAF1 / MEK / ERK Signaling Pathway. Cancer Science, 116(9), 2471-2485. https://doi.org/10.1111/cas.70132
Vancouver
Wu S, Hong Y, Li H, Lin M, Lin X, Lin X, et al. SHBs Mitigates Sorafenib‐Induced Apoptosis in Hepatocellular Carcinoma via Activation of RAF1 / MEK / ERK Signaling Pathway. Cancer Science. 2025;116(9):2471-2485. doi:10.1111/cas.70132
BibTeX
@article{Wu2025,
author = {Wu, Shuxiang and Hong, Yuxiang and Li, Hang and Lin, Mengxian and Lin, Xiaohuang and Lin, Xinjian and Lin, Xu},
title = {SHBs Mitigates Sorafenib‐Induced Apoptosis in Hepatocellular Carcinoma via Activation of RAF1 / MEK / ERK Signaling Pathway},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {9},
pages = {2471--2485},
doi = {10.1111/cas.70132}
}
EUVIMED